 |
| About |  |
Management | |
Advisors | |
Affiliates | |
For Entrepreneurs | |
Portfolio | |
News | |
Contact |
|
View our latest news below or select an archive.. Biotechs buoyed at Mid-Atlantic conference November 8, 2009 Established Maryland bioscience companies foresee a fairly promising investment atmosphere, as they made their pitches to venture capitalists attending the Mid-Atlantic Bio Conference on Friday. More than 750 participants, including more than 300 bioscience companies, atten... Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon October 22, 2009 LOUISVILLE, Ky., Oct. 23 /PRNewswire/ -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd.,... FASgen Receives New $1.4 Million NIH Grant for Obesity Research October 1, 2009 BALTIMORE--(BUSINESS WIRE)--FASgen, Inc. is pleased to announce that it was awarded a new $1.4 million SBIR Phase II NIH grant for continued research for obesity. FASgen has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway on the regulation o... MediQuest Therapeutics Takes Streamlined Route To VC Liquidity August 20, 2009 MediQuest Therapeutics Inc. is taking what it hopes will be a streamlined approach to providing liquidity for its venture backers: licensing out its portfolio of drug candidates and distributing the proceeds.Phased exit strategies such as this one are growing more common as venture firms search for ... Cytox Raises Pre-Series A Financing From Existing UK Investors, Welcomes First US Investor June 23, 2009 LONDON, June 24 /PRNewswire/ -- Cytox Limited, a UK-based neuroscience company that provides blood biomarker services to the pharmaceutical industry for Alzheimer's disease (AD) clinical trials, has announced completion of a pre-Series A funding round of GBP 600,000 (US$ 1 million). Proceeds wil... Potentia Pharmaceuticals Successfully Completes Phase I Clinical Trial May 3, 2009 LOUISVILLE, Ky., May 4 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it successfully completed its Phase I ASaP (Assessment of Safety of Intravitreal POT-4 Therap... Cytox Bolsters Support Through Stake By Masa Life Science Ventures April 5, 2009 VENTUREWIRE Monday, April 06, 2009 o Cytox Bolsters Support Through Stake By Masa Birmingham, U.K. -- Alzheimer's disease diagnostic developer Cytox Ltd. has raised an undisclosed amount of funding through Masa Life Science Ventures in an ongoing fund-raising, VentureWire has l... Medtronic and Envisionier Medical Technologies announce a distribution agreement February 5, 2009 Medtronic, Inc. (NYSE:MDT) and Envisionier Medical Technologies, Inc., a privately held company, today announced an agreement that grants exclusive rights for US distribution and marketing of the endogo® system to the ENT (ear, nose, and throat) division of Medtronic. Envisionier is the develop... The MaxCyte STX Scalable Transfection Presented at LabAutomation 2009 January 25, 2009 MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces the presentation of the MaxCyte® STX™ Scalable Transfection System at LabAutomation2009 in the Rapid Fire Innovation Session in Palm Springs, CA. “The selection of the MaxCyte STX ... FASgen, Inc. Announces Research and License Agreement With Centocor, Inc. (JNJ) January 5, 2009 BALTIMORE, Jan. 6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research and Development division affiliates the opportunity to discover and deve... MaxCyte Hosts LIVE Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery November 11, 2008 MaxCyte Hosts LIVE Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery For more details please follow this link: http://www.maxcyte.com/pdf/maxcyte_pr_111208.pdf... JADO Technologies Raises Second Round November 10, 2008 JADO Technologies GmbH, a Dresden, Germany-based developer of RAFT intervention therapeutics, has raised €3.9 million in Series B funding. Peppermint Financial Partners led the round, and was joined by NRW.Bank and return backers Dresden Fonds GmbH, EMBL Ventures, KfW (ERP-Startfonds), Max Pla... Potentia Pharmaceuticals Appoint Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board November 10, 2008 LOUISVILLE, KY – November 11, 2008 – Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today the appointments of Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to its Scient... The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays October 9, 2008 Please follow this link for full story: http://www.maxcyte.com/pdf/The_MaxCyte_STX_Scalable_Transfection_System_to_be_Launched_at_the_SBS_Symposium_on_Cell-Based_Assays.pdf... Potentia Pharmaceuticals Announces Positive Safety Data September 28, 2008 September 29, 2008—Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD) announced today that the Company's leading drug candidate, POT-4, has shown early positive safety results in its Phase I study. P... Potentia Poised for Validation in Complement Inhibition in AMD (BioWorld Today, September 2008) September 11, 2008 Please see full article at this link: http://potentiapharma.com/Bioworld_091208.pdf ... Potentia receives a Phase II STTR grant August 31, 2008 Potentia Pharmaceuticals, together with academic collaborators, received a Phase II STTR grant from the National Eye Institute to push forward their development of a new, less invasive delivery technology for ocular therapeutics. This grant, involving a collaboration with the Lions Eye Center of the... Medinet Starts Commercialization of Novel Cancer Immunotherapy Technology in Japan August 7, 2008 Please see this link for the full story: http://www.maxcyte.com/pdf/MaxCyte_Medinet_Joint_Press_Release_20_August_2008_FINAL.pdf ... JADO INITIATES PHASE II TRIALS OF LEAD RAFT MODULATOR IN URTICARIA July 1, 2008 JADO Technologies GmbH, the leading developer of RAFT intervention therapeutics, announced today the start of a Phase II study to evaluate the safety and efficacy of oral TF002, a formulation of miltefosine, in patients with antihistamine resistant urticaria. TF002 exerts anti-inflammatory activity ... Correlogic is granted new U.S. Patent June 30, 2008 Correlogic is granted U.S. Patent Number 7,395,160 for "Quality Assurance — Quality Control for Electrospray Ionization Processes". The patent covers important quality control methods to help ensure the validity of test results when blood serum is analyzed on a mass spectrometer. It compleme... Correlogic is granted new U.S. Patent June 30, 2008 Correlogic is granted U.S. Patent Number 7,395,160 for "Quality Assurance — Quality Control for Electrospray Ionization Processes". The patent covers important quality control methods to help ensure the validity of test results when blood serum is analyzed on a mass spectrometer. It compleme... JADO REPORTS CLINICAL PROOF OF CONCEPT WITH RAFT MODULATOR IN ATOPIC DERMATITIS June 1, 2008 JADO Technologies GmbH, the leading developer of RAFT intervention therapeutics, announced today positive results from a Phase IIa clinical trial of its lead RAFT modulator TF002 in patients with severe atopic dermatitis. TF002, a topical formulation of miltefosine, exerts its anti-inflammatory acti... FASgen and Tetracore Inc. enter collaboration May 28, 2008 BALTIMORE, May 29 /PRNewswire/ -- FASgen Diagnostics, LLC (Baltimore) and Tetracore, Inc. (Rockville) have announced that they have entered into a collaboration to produce cGMP ELISA and IHC tests for cancer biomarkers using FASgen's proprietary antibodies. The tests measure the over-expression of t... enGene Announces Issuance of Core Patent March 5, 2008 Vancouver, BC, Canada –March 6, 2008 – enGene Inc. announced today that the U.S. Patent and Trademark Office has issued US Patent 7,335,646, which grants enGene claim to a method to induce endocrine cells located in the gastrointestinal tract to synthesize and secrete different therape... NPR interview with Fred Dechow December 17, 2007 On BioTech Nation, Dr. Moira Gunn looks at a condition which afflicts 3-to-5% of Americans, and 90% of those affected are women. Fred Dechow, of Mediquest, explains Raynaud's, and that if you have it, you know how painful it can be. Please use the following link to hear the interviewhttp... CIMA NANOTECH SELECTED AS A 2008 TECHNOLOGY PIONEER November 28, 2007 (BY THE WORLD ECONOMIC FORUM) St. Paul, Minn., November 29, 2007 - The World Economic Forum today named 39 visionary companies as Technology Pioneers 2008. Cima NanoTech, Inc., based in St. Paul, Minnesota, has been selected as one of these Technology Pioneers for advancing the field of nanoma... BINEX AND MAXCYTE COLLABORATE ON CANCER IMMUNOTHERAPY RESEARCH November 27, 2007 Busan, Korea and Gaithersburg, MD - November 28, 2007 - Binex (KOSDAQ:053030) and MaxCyte, Inc. announced today the signing of a Sponsored Research Agreement to evaluate MaxCyte's GMP-compliant cell loading technology for use in closed-system manufacturing of Binex's cell-based cancer immu... Positive results for Raynaud's drug November 8, 2007 Bothell-based MediQuest Therapeutics said Thursday a late-stage clinical trial of its topical treatment for Raynaud's disease showed encouraging results. The treatment showed "significant improvement" in patients' symptoms of severe pain in their extremities. The results put the company "one step ... Emerging Drug Developer: MediQuest Therapeutics November 7, 2007 By john Created Nov 8 2007 - 3:37pmMediQuest's 13-year journey to commercialization It's been a long, winding road for MediQuest Therapeutics, but the tiny Bothell, WA-based biotech has just taken a big step toward commercializing its first product. Founded in 1994, MediQuest had to refocus four ... Bothell biotech secures patent October 29, 2007 MediQuest Therapeutics Inc. has received a European patent for a nontoxic treatment that can lighten skin. The Bothell company, which is developing topical treatments for inflammatory and infectious diseases, said its technology regulates an enzyme that produces skin pigment. While some people aroun... Patent obtained for skin lightening October 29, 2007 Bothell-based MediQuest Therapeutics said Monday that it has obtained a European patent for a technology that can be used to lighten skin. The technology inhibits the production of melanin and could be used to treat age spots and other skin ailments, the company said in a statement. MediQuest, a... JADO TECHNOLOGIES LICENSES CLINICAL DATA FROM AETERNA ZENTARIS FOR USE OF MILTEFOSINE IN ALLERGY INDICATIONS October 29, 2007 JADO Technologies, the leading developer of RAFT intervention therapeutics, announced today the licensing of exclusive access to preclinical and clinical data on miltefosine from AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) for development of the compound in allergy indications. Access to this dat... MediQuest wins European patent for skin treatment October 28, 2007 Bothell-based MediQuest Therapeutics Inc. said Monday that it had won a European patent for technology that can help lighten skin. The patented technology can regulate the amount of melanin that is produced. Melanin is the pigment produced in skin, hair and eyes. The company says the technology wo... Patent Awarded to MediQuest Therapeutics October 28, 2007 Company developing non-toxic skin lightening therapy BOTHELL, WA - Oct. 29 - MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing topical therapies for inflammatory and infectious diseases, today announced it was awarded a European patent for technology that c... MediQuest on the cusp of marketing first product September 5, 2007 By ANDREA JAMESP-I REPORTER If fortune -- cleverly disguised as the U.S. Food and Drug Administration -- smiles upon MediQuest Therapeutics Inc., 2008 could be the year that the small Bothell-based specialty biotech markets its first product. After 13 years of tinkering with drug formulas, MediQue... JADO TECHNOLOGIES APPOINTS NEW CHIEF EXECUTIVE OFFICER September 3, 2007 JADO Technologies, the leading developer of novel cell membrane-targeted drugs, today announced the appointment of Charl van Zyl as its new Chief Executive Officer. Charl van Zyl will take over from Dr. Gary Jennings, cofounder and former CEO/CSO, who will continue as Chief Scientific Officer. Cha... MEDINET LICENSES MAXCYTE CELL LOADING TECHNOLOGY FOR CANCER IMMUNOTHERAPY IN JAPAN August 26, 2007 Gaithersburg, MD, USA and Yokohama, Japan - August 27, 2007 - MaxCyte, Inc. and Medinet Co., Ltd. (TSE: #2370) announced today the signing of an exclusive license, development and supply agreement to use MaxCyte's proprietary cell loading system to support clinical studies and commercializ... MediQuest Hires Pharmaceutical Industry Veteran as Senior VP of Sales July 1, 2007 Media Contacts:Emily Zshornack-Topacio, MediQuestPhone: 425-398-9580; E-mail: emily@mqti.com Robert Gara, APCO WorldwidePhone: 206-239-0111; E-mail: rgara@apcoworldwide.com BOTHELL, WA - July 2 - MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing therapies for i... MediQuest Concludes Confirmatory Phase III Study of Raynaud's Therapy June 24, 2007 BOTHELL, WA - June 25 - MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing therapies for inflammatory and infectious diseases, today announced the completion of its confirmatory phase III study of Vascana - a topical formulation designed to treat Ra... MaxCyte and Medinet to present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia June 21, 2007 "Electroloading of mature dendritic cells with tumor lysate triggers robust antigen-specific CTL response" Gaithersburg, MD, and Yokohama, Japan - June 22, 2007 - MaxCyte, Inc. and Medinet Co., Ltd. (TSE: #2370) announce a joint poster presentation at the 13th Annual Meeting of the Internation... Vision Therapies Draw Backers May 22, 2007 By Brian Gormley Venture capitalists are bankrolling drug makers taking aim at a blinding disease that is incurable today. Nearly two million U.S. citizens suffer vision loss because of age-related macular degeneration, or AMD, according to the National Eye Institute, and millions more are believ... MaxCyte Announces Appointment Of Douglas A. Doerfler To Biotechnology Industry Organization's Board Of Directors May 13, 2007 Gaithersburg, MD, May 14, 2007 - MaxCyte, Inc., a clinical-stage cell therapeutics company with a growing pipeline of proprietary and partnered drug candidates, today announced that Douglas A. Doerfler, the Company's president, chief executive officer and director, has been elected to the Board... Envisionier signs a distribution agreement with ATOS Medical BV for distribution of the endogo® in the Netherlands April 16, 2007 FOR IMMEDIATE RELEASE: 1-FEB-2007 Rockville, Maryland Envisionier medical technologies today announced an agreement to market and distribute the endogo® endoscopic imaging system in the Netherlands with Atos Medical BV. This agreement marks the first entry of the endogo® in the ... Potentia Pharmaceuticals Announces Initiation of Phase I Clinical Trials to Evaluate its Lead Compound for Age-Related Macular Degeneration April 5, 2007 POT-4 is the first complement inhibitor for age-related macular degeneration to enter clinical phase of development LOUISVILLE, Ky., March 20 /PRNewswire/ -- Potentia Pharmaceuticals, Inc. announced today that it is entering the clinical phase of development for POT-4, its lead drug candidate f... Potentia Pharmaceuticals announces initiation of Phase I clinical trials to evaluate its lead compound for age-related macular degeneration March 19, 2007 March 20, 2007 - Potentia Pharmaceuticals, Inc. announced today that it is entering the clinical phase of development for POT-4, its lead drug candidate for the treatment of age-related macular degeneration (AMD). POT-4 is a complement inhibitor, which shuts down the complement activation system tha... Potentia Pharmaceuticals, Inc. Raises $5 Million from Private Investors March 6, 2007 LOUISVILLE, Ky., March 7 /PRNewswire/ -- Potentia Pharmaceuticals, Inc. announced today that it closed a $5 million round of financing. The funds will be used in part to support the pre-clinical and clinical development of Potentia's main drug candidate, POT-4. POT-4 is a derivative of Compstatin, a... MediQuest Hires Pharmaceutical Industry Veteran as VP, Clinical Development February 4, 2007 BOTHELL, WA - Feb. 5 - MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing therapies for inflammatory/infectious diseases that recently completed Phase IIIa clinical trials for a therapy designed to treat Raynaud's Disease, is pleased to announce that Eri... MaxCyte to Host Symposium at BIO Asia 2007 January 16, 2007 "Delivering on the Promise of Cellular Therapies" Gaithersburg, MD, January 17, 2007 - MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces that it is hosting a symposium on "Delivering on the Promise of Cellular Therapies... MaxCyte is a Featured Speaker at 2nd International Stem Cells and Regenerative Medicine 2007 January 15, 2007 "Engineering Cells for Clinical Regenerative Applications: A Practical Approach" Gaithersburg, MD, January 16, 2007 - MaxCyte, Inc., a clinical stage therapeutic company and pioneer in non-viral cell loading systems, announces Joseph Fratantoni, M.D. will be a featured speaker at the 2nd Inter... MaxCyte is Featured Speaker at the Phacilitate Cell and Gene Therapy Forum 2007 January 15, 2007 "Optimizing Production of Engineered Cell Therapies" Gaithersburg, MD, January 16, 2007 - MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces it will be a Co-Sponsor and featured speaker of the Phacilitate Cell and Gene T... NORTHERN THERAPEUTICS AND MAXCYTE INITIATE LANDMARK ENGINEERED CELL THERAPY TRIAL FOR FATAL LUNG DISEASE December 11, 2006 First Patient Treated in PHACeT Study at St. Michael’s Hospital in Toronto TORONTO, ON, and GAITHERSBURG, MD, December 12, 2006 - Northern Therapeutics, Inc., a Canadian biotechnology company, and MaxCyte, Inc., a U.S. therapeutics company, announced today the commencement of the first-ever ... MediQuest hires former CFO for Roche Consumer Health as new Chief Financial Officer November 27, 2006 Bothell, WA - Nov. 28, 2006 - MediQuest Therapeutics, Inc., a specialty pharmaceutical company that recently released results of a Phase IIIa clinical trial for a new potential therapy to treat Raynaud’s Disease, is pleased to announce that Douglas R. Sanders, MBA, has joined the company ... MediQuest drug moves forward November 23, 2006 By Eric FettersHerald Writer BOTHELL - MediQuest Therapeutics' treatment for a painful condition that affects the hands and toes of millions of people has shown promising results in late-stage clinical tests. The phase 3 study of its gel - tentatively called Vascana - showed both "statistically an... MaxCyte on track to raise $20M to fund cell research November 23, 2006 By Vandana Sinha Staff Reporter MaxCyte has rasied rearly $17 million in a second round of financing that could reach more than $20 million before it closes in six months. With the new venture capital, MaxCyte’s seven-year funding total is just shy of $25 million. Funds have... Vascana Phase IIIa clinical trial results hold promise for millions suffering from Raynaud's Disease November 12, 2006 (Bothell, WA - Nov. 13, 2006) Today MediQuest Therapeutics, Inc., a specialty pharmaceutical company, announced the results of its Phase IIIa clinical study of Vascana - a non-systemic, topical application designed to treat Raynaud's Disease - at the annual American College of Rheumatology (ACR) mee... MediQuest Therapeutics, Inc. Announces Addition to Management Team October 15, 2006 (Bothell, WA - 16 October, 2006) MediQuest Therapeutics, Inc. a privately held biotechnology company specializing in infectious and inflammatory skin diseases today announced that Allison Formal, MBA, has joined MediQuest as its vice president for business development. Formal will be part of the com... MaxCyte Strengthens Leadership Team September 12, 2006 Arthur Mandell elected to Board of DirectorsJudith Hedstrom joins as SVP, Corporate and Business DevelopmentCarl June, M.D. added to Scientific and Medical Advisors Gaithersburg, MD, September 13, 2006 - MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale cell loa... MaxCyte To Present at Bio Korea, BioJapan and Global Venture Forum Japan August 22, 2006 Gaithersburg, MD, August 23, 2006 - MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announced today that Douglas Kolodny-Hirsch, Ph.D., Senior Director Business Development, will be presenting at the Bio Korea 2006 Conference in Seou... MEDINET AND MAXCYTE INITIATE COLLABORATION FOR NOVEL CANCER IMMUNO-CELL THERAPY August 15, 2006 Amended August 22, 2006 from original release dated August 16, 2006: Gaithersburg, MD and Yokohama, Japan – August 16, 2006 – MaxCyte, Inc. and Medinet Co., Ltd. announced the signing of a collaboration agreement, made on August 9, 2006. Under this greement MaxCyte will optimize its pro... Potentia Pharmaceuticals licences complement inhibitor Compstatin from the University of Pennsylvania July 26, 2006 July 27, 2006 - Potentia Pharmaceuticals, Inc. announced today that it has entered into an exclusive, worldwide licensing agreement with the University of Pennsylvania that provides broad rights to develop and commercialize University of Pennsylvania's Compstatin class of complement-inhibiting pepti... MediQuest Adds Gregory As VP And Chief Medical Officer July 13, 2006 MediQuest Therapeutics Inc., a developer of treatments for infectious and inflammatory skin diseases and conditions, said it has named Jeff Gregory to the position of vice president for medical affairs and chief medical officer. This is a newly created position at MediQuest, a company spokeswoman s... MediQuest Therapeutics Raises $16M Series A June 15, 2006 By Lorie Konish MediQuest Therapeutics Inc., a biotechnology company developing treatments for infectious and inflammatory skin diseases and conditions, said it has closed a $16 million Series A funding round. The Series A round was led by Integra Ventures and Novo A/S. Other participants in the ... Potentia Pharmaceuticals awarded Phase I STTR grants from the National Eye Institute May 31, 2006 Potentia Pharmaceuticals, together with academic collaborators, received two Phase I STTR grants from the National Eye Institute to develop new, less invasive delivery technologies for ocular therapeutics. The first grant, involving a collaboration with the Lions Eye Center of the University of Loui... Fellowship Ranks Swell With Big 2006 Class May 11, 2006 Private Equity Insider, May 12thFellowship Ranks Swell With Big 2006 Class Article by Tracey Regan, Senior Writer, PEI Several up-and-coming venture capitalists received notice this week that they have won Kauffman fellowships, coveted two-year apprenticeships served under some of the industry's m... Potentia Pharmaceuticals hosts reception at the 2006 ARVO annual meeting in Fort Lauderdale April 2, 2006 Potentia hosted a reception in Fort Lauderdale during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. The event brought together the entire Potentia team and Scientific Advisory Board, along with collaborators and potential partners and introduced them to Potentia and... SANGAMO BIOSCIENCES LICENSES MAXCYTE CELL LOADING TECHNOLOGY FOR ZFP THERAPEUTIC PROGRAM FOR HIV/AIDS March 1, 2006 Gaithersburg, MD and Richmond, CA - March [2], 2006 – MaxCyte, Inc. and Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today a license, option, development, and supply agreement to utilize MaxCyte's proprietary cell loading system for use in Sangamo's HIV/CCR5 ZFP Therapeutic™ p... GERON LICENSES MAXCYTE CELL LOADING TECHNOLOGY FOR USE IN CLOSED-SYSTEM CANCER VACCINE MANUFACTURING February 14, 2006 Gaithersburg, MD and Menlo Park, CA - February 15, 2006 - MaxCyte, Inc. and Geron Corporation (Nasdaq: GERN) announced today a license, option, development, and supply agreement to utilize MaxCyte's proprietary cell loading system in the manufacture of mRNA-loaded dendritic cell-based vaccines,... MediQuest Therapeutics Receives Special Protocol Assessment from the U.S. FDA January 9, 2006 (Bothell, WA - 10 January 2006). MediQuest Therapeutics, Inc. today announced that it has received recommendations from the U.S. Food and Drug Administration (FDA) under the Special Clinical Protocol Assessment (SCPA) procedure with respect to their protocol on a Phase III "in-life" study of a topic... MediQuest Therapeutics, Inc. Enrolls Patients in its Phase IIB Clinical Study for the Treatment of Onychomycosis (Toenail Fungus) January 3, 2006 (Bothell, WA - 4 January 2006). MediQuest Therapeutics, Inc. today announced that it is enrolling patients in its U.S. Phase IIB clinical study for treating onychomycosis, more commonly known as toenail fungus. The therapeutic agents, which are FDA-approved anti-fungal agents, are formulated into Me... Masa Closes On Half Of Projected $30M Life Science Fund July 24, 2005 By Alex Halperin, Dow Jones VentureWire7/25/2005. Advisory firm Masa Inc. has closed on about half of a $30 million life science fund that will aim to unite capital from Japan and Korea with North American technologies, A. Sinclair Dunlop, Masa's director of new business ventures, told VentureWir... |
